| [1] | Xin SHI, Chongxiao LIANG, Bei ZHANG, Jiping WANG. Value of internal stratification analysis of abdominal wall muscles in predicting complications after orthotopic liver transplantation[J]. Journal of Clinical Hepatology, 2025, 41(2): 314-321. doi: 10.12449/JCH250218 |
| [2] | Nutrition Journal｜Effects of vitamin D supplementation on liver fibrogenic factors, vitamin D receptor and liver fibrogenic microRNAs in metabolic dysfunction-associated steatotic liver disease (MASLD) patients: an exploratory randomized clinical trial[J]. Journal of Clinical Hepatology, 2024, 40(8): 1626-1626. doi: 10.12449/JCH2408.gwqkjpwzjj2 |
| [3] | Hepatology International｜Clinic-radiomics model using liver magnetic resonance imaging helps predict chronicity of drug-induced liver injury[J]. Journal of Clinical Hepatology, 2024, 40(2): 270-270. doi: 10.12449/JCH2402.gwqkjpwzjj2 |
| [4] | Xinyi LI, Jiaojiao LI, Wei SUN. Establishment and evaluation of a nomogram prediction model for overt hepatic encephalopathy after transjugular intrahepatic portosystemic shunt in patients with liver cirrhosis and esophagogastric variceal bleeding[J]. Journal of Clinical Hepatology, 2024, 40(8): 1605-1611. doi: 10.12449/JCH240816 |
| [5] | Lanjing WANG, Jianping QIN, Xin YAO, Qi QI, Lin LIU, Shanhong TANG. Construction of a risk prediction model for overt hepatic encephalopathy after transjugular intrahepatic portosystemic shunt in patients with hepatitis B cirrhosis and portal hypertension[J]. Journal of Clinical Hepatology, 2024, 40(6): 1149-1155. doi: 10.12449/JCH240613 |
| [6] | Qi QI, Xin YAO, Guodong YANG, Jianping QIN. Research advances in the influence of intraoperative factors during transjugular intrahepatic portosystemic shunt on the development of hepatic encephalopathy[J]. Journal of Clinical Hepatology, 2023, 39(8): 1966-1971. doi: 10.3969/j.issn.1001-5256.2023.08.030 |
| [7] | Hepatology｜Concurrent large spontaneous portosystemic shunt embolization for the prevention of overt hepatic encephalopathy after TIPS: A randomized controlled trial[J]. Journal of Clinical Hepatology, 2022, 38(10): 2285-2285. doi: 10.3969/j.issn.1001-5256.2022.10.gwjpwzjj2 |
| [8] | Menghao LI, Kai LI, Shihao TANG, Zhengyu WANG, Wengang GUO, Zhanxin YIN, Guohong HAN. Changes in gut microbiota after transjugular intrahepatic portosystemic shunt in cirrhotic patients with mild hepatic encephalopathy in different prognosis groups[J]. Journal of Clinical Hepatology, 2021, 37(2): 326-330. doi: 10.3969/j.issn.1001-5256.2021.02.016 |
| [9] | Gonghai CHEN, Guangchuan WANG, Chunqing ZHANG. Current status of research on hepatic encephalopathy after transjugular intrahepatic portosystemic shunt[J]. Journal of Clinical Hepatology, 2021, 37(5): 1201-1204. doi: 10.3969/j.issn.1001-5256.2021.05.047 |
| [10] | Yao YunHai, Luo Yan, Zhu JingLe, Gan JianHe, Zhao WeiFeng. Risk factors for hepatic encephalopathy after emergency transjugular intrahepatic portosystemic shunt for patients with acute esophagogastric variceal bleeding[J]. Journal of Clinical Hepatology, 2020, 36(2): 343-347. doi: 10.3969/j.issn.1001-5256.2020.02.022 |
| [11] | Wang Zhong, Yue ZhenDong, Zhao HongWei, Wang Lei, Fan ZhenHua, Wu YiFan, Dong ChengBin, Zhang Yu, Liu FuQuan. Value of indocyanine green retention rate at 15 minutes in predicting the risk of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt in liver cancer patients with portal hypertension[J]. Journal of Clinical Hepatology, 2020, 36(9): 1994-1997. doi: 10.3969/j.issn.1001-5256.2020.09.017 |
| [12] | ZHONG XiaoSheng, LIU YiFeng, LIU ZhangYuanZhu, CHEN GuiHao, WU Xiang, HUANG YouXing, CHOU ChengJiang, ZHANG Sheng, CAI ShiXia, TAN ZhiJian, SHEN ZhanTao. Application of 3D laparoscopy in pancreaticoduodenectomy[J]. Journal of Clinical Hepatology, 2020, 36(12): 2655-2658. doi: 10.3969/j.issn.1001-5256.2020.12.004 |
| [14] | He ChuangYe, Chen Hui, Lyu Yong, Xia DongDong, Yu TianLei, Yuan XuLong, Li Kai, Wang ZhengYu, Niu Jing, Bai Wei, Guo WenGang, Tie Jun, Yin ZhanXin, Han GuoHong. Safety and efficacy of flow-reducing stent in treatment of recurrent or persistent hepatic encephalopathy after transjugular intrahepatic portosystemic shunt[J]. Journal of Clinical Hepatology, 2019, 35(8): 1719-1722. doi: 10.3969/j.issn.1001-5256.2019.08.014 |
| [15] | Wang Zhong, Liu FuQuan. Research advances in hepatic encephalopathy after transjugular intrahepatic portosystemic shunt[J]. Journal of Clinical Hepatology, 2019, 35(12): 2824-2827. doi: 10.3969/j.issn.1001-5256.2019.12.040 |
| [16] | Jiang MingYuan, Huang Hua, Lu MingLiang, Lin FanYu, Zhang YingYuan. Application of anticoagulants after transjugular intrahepatic portosystemic shunt[J]. Journal of Clinical Hepatology, 2018, 34(10): 2241-2244. doi: 10.3969/j.issn.1001-5256.2018.10.040 |
| [18] | Ren ShuYao, Chen Hui, Lu: Yong, Wang ZhengYu, Niu Jing, Yin ZhanXin, He ChuangYe, Guo WenGang, Han GuoHong. Hepatic myelopathy after transjugular intrahepatic portosystemic shunt:natural course,survival analysis,and treatment[J]. Journal of Clinical Hepatology, 2016, 32(6): 1112-1117. doi: 10.3969/j.issn.1001-5256.2016.06.018 |
| [19] | Wang TingTing, Zhang Feng, ZhuGe YuZheng. Research progress in TIPS shunt dysfunction and recanalization[J]. Journal of Clinical Hepatology, 2015, 31(11): 1921-1923. doi: 10.3969/j.issn.1001-5256.2015.11.041 |
DownLoad: